Key Highlights

  • Immuron shares closed up 62% at $1.80.
  • The company entered an exclusive U.S. distribution agreement with Calmino Group AB for PROIBS.
  • PROIBS is a medical device certified in Europe for treating bloating, abdominal discomfort, and bowel irregularity.
  • The deal broadens Immuron's digestive wellness lineup alongside its existing Travelan product.

Immuron Limited (NASDAQ: IMRN) shares closed up 62% at $1.80 after the company entered an exclusive distribution agreement within the United States with Calmino Group AB for PROIBS.

What Happened

PROIBS is a medical device certified in Europe for treating bloating, abdominal discomfort, and bowel irregularity, broadening Immuron's digestive wellness lineup alongside Travelan. While the news expands the company's commercial footprint, the development remains focused on distribution rather than clinical trials, regulatory milestones, or Capital raises.

Market Reaction

Shares surged sharply as investors responded to the new distribution channel, a significant move for a company of Immuron's size even though the announcement did not include new clinical or regulatory data.

Outlook

Continued commercial rollout of PROIBS within the U.S. market represents the next relevant development for Immuron's digestive wellness portfolio.